23/47
2.4 / 5 stars
All 47 Win/Lose results and 73 gray no-data contests shown below
VRCA Roast Me summary
Verrica Pharmaceuticals Inc. (VRCA). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth No data.
Trailing 1 year (4 quarters): 6 wins, 2 losses, 4 no dataLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/2 |
WinVRCA / S&P 15.69% / 15.20% |
WinVRCA / S&P 106.21% / 15.00% |
No dataVRCA / S&P / 50.40% |
| 2026-Q11/2 |
LoseVRCA / S&P -36.34% / -4.33% |
WinVRCA / S&P 417.63% / 11.30% |
No dataVRCA / S&P / 27.70% |
| 2025-Q42/2 |
WinVRCA / S&P 92.81% / 2.65% |
WinVRCA / S&P 370.22% / 9.00% |
No dataVRCA / S&P / 13.40% |
| 2025-Q31/2 |
LoseVRCA / S&P -18.68% / 8.12% |
WinVRCA / S&P 234.73% / 4.61% |
No dataVRCA / S&P / 13.45% |
| 2025-Q22/2 |
WinVRCA / S&P 19.91% / 10.94% |
WinVRCA / S&P 5.72% / 4.83% |
No dataVRCA / S&P / 10.63% |
| 2025-Q10/2 |
LoseVRCA / S&P -36.86% / -4.27% |
LoseVRCA / S&P -19.45% / 4.98% |
No dataVRCA / S&P / 10.57% |
| 2024-Q41/2 |
LoseVRCA / S&P -51.72% / 2.41% |
WinVRCA / S&P 47.66% / 5.25% |
No dataVRCA / S&P / 6.15% |
| 2024-Q31/2 |
LoseVRCA / S&P -80.11% / 5.89% |
WinVRCA / S&P 187.45% / 5.89% |
No dataVRCA / S&P / 6.11% |
| 2024-Q22/2 |
WinVRCA / S&P 23.14% / 4.28% |
WinVRCA / S&P 61.61% / 5.38% |
No dataVRCA / S&P / 5.12% |
| 2024-Q10/2 |
LoseVRCA / S&P -19.13% / 10.56% |
LoseVRCA / S&P 3.18% / 5.71% |
No dataVRCA / S&P / 5.59% |
| 2023-Q41/2 |
WinVRCA / S&P 88.42% / 11.69% |
LoseVRCA / S&P -43.27% / 6.81% |
No dataVRCA / S&P / 7.78% |
| 2023-Q30/2 |
LoseVRCA / S&P -32.67% / -3.27% |
LoseVRCA / S&P -64.26% / 7.52% |
No dataVRCA / S&P / -5.03% |
| 2023-Q21/2 |
LoseVRCA / S&P -11.23% / 8.74% |
WinVRCA / S&P 1234.26% / 9.50% |
No dataVRCA / S&P / -8.57% |
| 2023-Q12/2 |
WinVRCA / S&P 136.36% / 7.50% |
WinVRCA / S&P 1904.18% / 10.77% |
No dataVRCA / S&P / -15.69% |
| 2022-Q40/2 |
LoseVRCA / S&P -5.82% / 7.56% |
LoseVRCA / S&P -24.73% / 11.88% |
No dataVRCA / S&P / -17.99% |
| 2022-Q31/1 |
WinVRCA / S&P 52.08% / -4.88% |
No dataVRCA / S&P / 13.47% |
No dataVRCA / S&P / -1.41% |
| 2022-Q20/1 |
LoseVRCA / S&P -76.33% / -16.10% |
No dataVRCA / S&P / 13.71% |
No dataVRCA / S&P / 11.04% |
| 2022-Q10/1 |
LoseVRCA / S&P -11.46% / -4.60% |
No dataVRCA / S&P / 15.97% |
No dataVRCA / S&P / 42.23% |
| 2021-Q40/1 |
LoseVRCA / S&P -26.72% / 11.03% |
No dataVRCA / S&P / 15.00% |
No dataVRCA / S&P / 96.40% |
| 2021-Q31/1 |
WinVRCA / S&P 10.62% / 0.58% |
No dataVRCA / S&P / 10.77% |
No dataVRCA / S&P / 69.42% |
| 2021-Q20/1 |
LoseVRCA / S&P -25.41% / 8.55% |
No dataVRCA / S&P / 6.58% |
No dataVRCA / S&P / 51.81% |
| 2021-Q11/1 |
WinVRCA / S&P 31.62% / 6.17% |
No dataVRCA / S&P / -1.06% |
No dataVRCA / S&P / 7.39% |
| 2020-Q41/1 |
WinVRCA / S&P 48.71% / 12.15% |
No dataVRCA / S&P / -3.72% |
No dataVRCA / S&P / -33.42% |
| 2020-Q30/1 |
LoseVRCA / S&P -29.70% / 8.93% |
No dataVRCA / S&P / -2.04% |
No dataVRCA / S&P / -27.10% |
| 2020-Q20/1 |
LoseVRCA / S&P 0.73% / 20.54% |
No dataVRCA / S&P / -0.46% |
No dataVRCA / S&P / -27.11% |
| 2020-Q10/1 |
LoseVRCA / S&P -31.21% / -19.60% |
No dataVRCA / S&P / 3.47% |
No dataVRCA / S&P / -14.75% |
| 2019-Q40/1 |
LoseVRCA / S&P 7.66% / 9.07% |
No dataVRCA / S&P / 5.36% |
No dataVRCA / S&P / 2.99% |
| 2019-Q31/1 |
WinVRCA / S&P 27.02% / 1.70% |
No dataVRCA / S&P / 5.02% |
No dataVRCA / S&P / 0.21% |
| 2019-Q21/1 |
WinVRCA / S&P 7.49% / 4.30% |
No dataVRCA / S&P / 6.64% |
No dataVRCA / S&P / 8.65% |
| 2019-Q11/1 |
WinVRCA / S&P 32.64% / 13.65% |
No dataVRCA / S&P / 8.12% |
No dataVRCA / S&P / 14.29% |
| 2018-Q40/1 |
LoseVRCA / S&P -49.85% / -13.52% |
No dataVRCA / S&P / 9.05% |
No dataVRCA / S&P / 18.23% |
| 2018-Q30/1 |
LoseVRCA / S&P -17.64% / 7.71% |
No dataVRCA / S&P / 10.21% |
No dataVRCA / S&P / 19.06% |
| 2018-Q20/0 |
No dataVRCA / S&P / 3.43% |
No dataVRCA / S&P / 9.03% |
No dataVRCA / S&P / 14.46% |
| 2018-Q10/0 |
No dataVRCA / S&P / -0.76% |
No dataVRCA / S&P / 7.68% |
No dataVRCA / S&P / 12.46% |
| 2017-Q40/0 |
No dataVRCA / S&P / 6.64% |
No dataVRCA / S&P / 7.03% |
No dataVRCA / S&P / 13.82% |
| 2017-Q30/0 |
No dataVRCA / S&P / 4.48% |
No dataVRCA / S&P / 5.68% |
No dataVRCA / S&P / 17.57% |
| 2017-Q20/0 |
No dataVRCA / S&P / 3.09% |
No dataVRCA / S&P / 4.83% |
No dataVRCA / S&P / 17.74% |
| 2017-Q10/0 |
No dataVRCA / S&P / 6.07% |
No dataVRCA / S&P / 3.67% |
No dataVRCA / S&P / 13.32% |
| 2016-Q40/0 |
No dataVRCA / S&P / 3.82% |
No dataVRCA / S&P / 2.09% |
No dataVRCA / S&P / 7.05% |
| 2016-Q30/0 |
No dataVRCA / S&P / 3.85% |
No dataVRCA / S&P / 0.20% |
No dataVRCA / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | VRCA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 4.57% | 20.78% |
| Annualized return | 4.57% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | VRCA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.87% | 83.14% |
| Annualized return | -44.78% | 12.86% |
10Y · 2018-06-15 to 2026-08-28
| Metric | VRCA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.66% | 319.30% |
| Annualized return | -28.81% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |